Adverse Effects of Antipsychotic Drugs
- First Online:
- 11 Downloads
Since the introduction of chlorpromazine in the 1950s, neuroleptic medications have been the mainstay of treatment of schizophrenia and other psychotic disorders. These medications do not always lead to complete remission of symptoms but they have allowed many patients to lead more productive and satisfying lives away from the restrictions of chronic hospitalisation. However, neuroleptics are associated with a number of adverse effects that can compromise their effectiveness. Extrapyramidal adverse effects include acute dystonic reactions, neuroleptic-induced Parkinsonism and akathisia. They can often be treated with neuroleptic dose reduction, addition of anticholinergic or β-blocking agents, or medication change. Later-onset movement disorders such as tardive dyskinesia or dystonia require careful evaluation and may be treated with dose reduction or change of neuroleptic to an atypical agent. Potentially fatal reactions such as agranulocytosis and neuroleptic malignant syndrome can rarely occur and often require significant medical intervention. Clozapine offers some advantages over ‘typical’ neuroleptics but has a unique adverse effect profile which includes agranulocytosis.
Unable to display preview. Download preview PDF.
- Bernstein J. Antipsychotic drugs. In Bernstein (Ed.) Drug therapy in psychiatry, 2nd ed., pp. 79–122, PSG Publishing Co. Inc., Littleton, 1988Google Scholar
- Casey DE. Tardive dyskinesia. In Meltzer (Ed.) Psychopharmacology the third generation of progress, pp. 1411–1419, Raven Press, New York, 1987Google Scholar
- Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, et al. Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacology Bulletin 20a: 387–389, 1984Google Scholar
- Kaufman DM. Clinical neurology for psychiatrists, 2nd ed., Grune and Stratton Inc., Orlando, 1985Google Scholar
- Pickar D. Pharmacotherapeutic approaches to schizophrenia. Presented at Psychopharmacology in Practice: Clinical and Research Update 1989, Bethesda, Maryland, November 3–4, 1989Google Scholar
- Pickar D, Owen RR, Litman RE. New developments in the pharmacotherapy of schizophrenia. Presented at Psychopharmacology in Practice: Clinical and Research Update 1991, Bethesda, Maryland, November 8–9, 1991Google Scholar
- Rifkin A, Siris S. Drug treatment of acute schizophrenia. In Meitzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1095–1101, Raven Press, New York, 1987Google Scholar
- Wyatt RJ. Untoward effects of neuroleptic treatment. Presented at Psychopharmacology in Practice: Clinical and Research Update 1989, Bethesda, Maryland, November 3–4, 1989Google Scholar